Mimedx Group, Inc. (MDXG)

$7.4

+0.24

(+3.35%)

Market is closed - opens 7 PM, 23 Jul 2024

Performance

  • $7.19
    $7.42
    $7.40
    downward going graph

    2.91%

    Downside

    Day's Volatility :3.17%

    Upside

    0.27%

    downward going graph
  • $5.57
    $9.27
    $7.40
    downward going graph

    24.73%

    Downside

    52 Weeks Volatility :39.91%

    Upside

    20.17%

    downward going graph

Returns

PeriodMimedx Group, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
13.67%
5.3%
0.0%
6 Months
-12.01%
6.3%
0.0%
1 Year
-0.8%
9.2%
0.0%
3 Years
-37.39%
13.1%
-19.9%

Highlights

Market Capitalization
1.1B
Book Value
$1.06
Earnings Per Share (EPS)
0.52
PE Ratio
13.77
PEG Ratio
2.97
Wall Street Target Price
12.43
Profit Margin
21.67%
Operating Margin TTM
15.64%
Return On Assets TTM
16.26%
Return On Equity TTM
68.13%
Revenue TTM
334.5M
Revenue Per Share TTM
2.69
Quarterly Revenue Growth YOY
18.2%
Gross Profit TTM
219.5M
EBITDA
54.0M
Diluted Eps TTM
0.52
Quarterly Earnings Growth YOY
4.0
EPS Estimate Current Year
0.3
EPS Estimate Next Year
0.38
EPS Estimate Current Quarter
0.04
EPS Estimate Next Quarter
0.08

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Mimedx Group, Inc.(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 67.97%

Current $7.40
Target $12.43

Company Financials

FY18Y/Y Change
Revenue
359.1M
↑ 11.82%
Net Income
-30.0M
↓ 146.32%
Net Profit Margin
-8.35%
↓ 28.51%
FY19Y/Y Change
Revenue
359.1M
↑ 0.0%
Net Income
-30.0M
↑ 0.0%
Net Profit Margin
-8.35%
↑ 0.0%
FY20Y/Y Change
Revenue
299.3M
↓ 16.67%
Net Income
-25.6M
↓ 14.67%
Net Profit Margin
-8.55%
↓ 0.2%
FY21Y/Y Change
Revenue
258.6M
↓ 13.58%
Net Income
-10.3M
↓ 59.79%
Net Profit Margin
-3.98%
↑ 4.57%
FY22Y/Y Change
Revenue
267.8M
↑ 3.57%
Net Income
-30.2M
↑ 193.6%
Net Profit Margin
-11.27%
↓ 7.29%
FY23Y/Y Change
Revenue
321.5M
↑ 20.03%
Net Income
67.4M
↓ 323.33%
Net Profit Margin
20.98%
↑ 32.25%
Q4 FY22Q/Q Change
Revenue
74.4M
↑ 9.88%
Net Income
-415.0K
↓ 95.07%
Net Profit Margin
-0.56%
↑ 11.89%
Q1 FY23Q/Q Change
Revenue
71.7M
↓ 3.63%
Net Income
-5.0M
↑ 1100.72%
Net Profit Margin
-6.95%
↓ 6.39%
Q2 FY23Q/Q Change
Revenue
81.3M
↑ 13.37%
Net Income
1.2M
↓ 124.08%
Net Profit Margin
1.48%
↑ 8.43%
Q3 FY23Q/Q Change
Revenue
81.7M
↑ 0.56%
Net Income
6.8M
↑ 463.42%
Net Profit Margin
8.27%
↑ 6.79%
Q4 FY23Q/Q Change
Revenue
86.8M
↑ 6.27%
Net Income
62.7M
↑ 827.2%
Net Profit Margin
72.19%
↑ 63.92%
Q1 FY24Q/Q Change
Revenue
84.7M
↓ 2.44%
Net Income
9.3M
↓ 85.23%
Net Profit Margin
10.93%
↓ 61.26%
FY18Y/Y Change
Total Assets
122.8M
↑ 1.31%
Total Liabilities
73.2M
↑ 54.22%
FY19Y/Y Change
Total Assets
122.8M
↑ 0.0%
Total Liabilities
73.2M
↑ 0.0%
FY20Y/Y Change
Total Assets
167.2M
↑ 36.08%
Total Liabilities
132.8M
↑ 81.4%
FY21Y/Y Change
Total Assets
187.9M
↑ 12.42%
Total Liabilities
187.8M
↑ 41.49%
FY22Y/Y Change
Total Assets
171.4M
↓ 8.78%
Total Liabilities
189.4M
↑ 0.84%
FY23Y/Y Change
Total Assets
239.0M
↑ 39.44%
Total Liabilities
96.3M
↓ 49.14%
Q4 FY22Q/Q Change
Total Assets
171.4M
↓ 0.79%
Total Liabilities
189.4M
↓ 1.51%
Q1 FY23Q/Q Change
Total Assets
168.2M
↓ 1.91%
Total Liabilities
186.1M
↓ 1.75%
Q2 FY23Q/Q Change
Total Assets
176.4M
↑ 4.89%
Total Liabilities
189.0M
↑ 1.58%
Q3 FY23Q/Q Change
Total Assets
189.0M
↑ 7.17%
Total Liabilities
187.7M
↓ 0.72%
Q4 FY23Q/Q Change
Total Assets
239.0M
↑ 26.47%
Total Liabilities
96.3M
↓ 48.68%
Q1 FY24Q/Q Change
Total Assets
221.7M
↓ 7.26%
Total Liabilities
66.0M
↓ 31.54%
FY18Y/Y Change
Operating Cash Flow
35.8M
↓ 43.13%
Investing Cash Flow
-9.2M
↑ 70.84%
Financing Cash Flow
-8.9M
↓ 85.21%
FY19Y/Y Change
Operating Cash Flow
35.8M
↑ 0.0%
Investing Cash Flow
504.0K
↓ 105.47%
Financing Cash Flow
-8.9M
↑ 0.0%
FY20Y/Y Change
Operating Cash Flow
-39.4M
↓ 210.1%
Investing Cash Flow
-4.6M
↓ 1003.77%
Financing Cash Flow
62.9M
↓ 803.59%
FY21Y/Y Change
Operating Cash Flow
-2.0M
↓ 94.97%
Investing Cash Flow
-3.4M
↓ 25.47%
Financing Cash Flow
-3.4M
↓ 105.33%
FY22Y/Y Change
Operating Cash Flow
-17.9M
↑ 802.77%
Investing Cash Flow
-2.7M
↓ 21.65%
Financing Cash Flow
-580.0K
↓ 82.7%
Q4 FY22Q/Q Change
Operating Cash Flow
-5.6M
↓ 686.44%
Investing Cash Flow
-1.7M
↑ 356.95%
Financing Cash Flow
66.0K
↓ 49.23%
Q1 FY23Q/Q Change
Operating Cash Flow
-4.0M
↓ 28.02%
Investing Cash Flow
-677.0K
↓ 60.39%
Financing Cash Flow
-4.0K
↓ 106.06%
Q2 FY23Q/Q Change
Operating Cash Flow
7.8M
↓ 292.07%
Investing Cash Flow
-348.0K
↓ 48.6%
Financing Cash Flow
4.0K
↓ 200.0%

Technicals Summary

Sell

Neutral

Buy

Mimedx Group, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Mimedx Group, Inc.
Mimedx Group, Inc.
8.82%
-12.01%
-0.8%
-37.39%
2.35%
Moderna, Inc.
Moderna, Inc.
-10.58%
20.19%
-0.41%
-64.88%
800.74%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.55%
12.06%
47.12%
82.44%
245.9%
Novo Nordisk A/s
Novo Nordisk A/s
-6.4%
26.39%
64.35%
193.51%
440.83%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.41%
12.78%
38.89%
147.34%
182.99%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Mimedx Group, Inc.
Mimedx Group, Inc.
13.77
13.77
2.97
0.3
0.68
0.16
NA
1.06
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.45
31.45
1.46
44.4
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.05
45.05
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Mimedx Group, Inc.
Mimedx Group, Inc.
Buy
$1.1B
2.35%
13.77
21.67%
Moderna, Inc.
Moderna, Inc.
Buy
$46.4B
800.74%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.2B
245.9%
31.45
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$591.7B
440.83%
45.05
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
182.99%
31.94
39.46%

Insights on Mimedx Group, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 86.83M → 84.70M (in $), with an average decrease of 2.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 62.68M → 9.26M (in $), with an average decrease of 85.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 60.8% return, outperforming this stock by 63.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 193.5% return, outperforming this stock by 230.9%

Institutional Holdings

  • Essex Woodlands Health Ventures

    19.10%
  • BlackRock Inc

    6.21%
  • Vanguard Group Inc

    4.01%
  • State Street Corporation

    3.35%
  • Paradigm Capital Management, Inc.

    2.65%
  • Trigran Investments Inc

    2.21%

Company Information

mimedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. the company processes the human placental tissue utilizing its proprietary purion® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. mimedx has supplied more than two million allografts, through both direct and consignment shipments. for additional information, please visit www.mimedx.com.

Organization
Mimedx Group, Inc.
Employees
895
CEO
Mr. William F. Hulse IV
Industry
Biotechnology

FAQs